Hottub News

Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLL

1 report from 1 outlet in 1 language · first reported · updated · JSON

HealthLillypirtobrutinibchronic lymphocytic leukemia and small lymphocytic lymphoma

Reports

  1. Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLLprnewswire.com · en ·

More in Health

  1. Democratic Republic of Congo: More than 4,000 people in the DR Congo have died from Ebola104 outlets
  2. Doctors warn about the risks energy drinks pose to kids. What families need to know73 outlets
  3. More than 4000 Ebola deaths in Democratic Republic of Congo65 outlets
  4. Cat food investigation finds heavy metals, pesticides and plastic chemicals36 outlets
  5. Life expectancy almost back to pre-Covid levels, says WHO47 outlets
  6. Synthetic bee silk set to take sting out of wounds43 outlets